Here are the five most-read Becker's ASC Review articles for gastroenterologists the week of May 4-8:
GI & Endoscopy
Exact Sciences posted first-quarter 2020 revenues of $347.8 million, a 114 percent year-over-year increase.
The administrator of a Colorado GI practice said the practice is starting to see its elective procedure volumes return, in a May 7 article in the Greeley Tribune.
Here are six updates from gastroenterology companies and practices from the past week:
Motus GI secured a U.S. patent for its Pure-Vu System's sensing technology and suction control features.
Medicare beneficiaries may engage with a multi-target stool DNA test better than a fecal immunochemical test, according to a study debuted digitally at Digestive Disease Week 2020.
Thompson Health Gastroenterology is relocating to a new outpatient clinic May 4, the Daily Messenger reports.
The American Gastroenterological Association released a guideline on the consultative management of COVID-19 patients.
CellMax Life released results from its U.S. study of the FirstSight blood test that revealed the test detected colorectal cancer with 100 percent sensitivity at 90 percent specificity.
Phoenix-based Arizona Digestive Health expects patient volumes in May will be just a fraction of what they were before the pandemic, gastroenterologist Paul Berggreen, MD, told Medscape Medical News.
